Table 2.
Clinical characteristics of patients with systemic sclerosis
| Clinical Characteristic | Primary Cohort | Secondary Cohort | |
|---|---|---|---|
| Mean ± Standard Deviation or as indicated | SSc patients (n = 6) | SSc patients (n = 60) | Healthy controls (n = 16) |
| Age | 54 ± 6 | 50 ± 11 | 42 ± 12 |
| Women (n, %) | 5 (83%) | 52 (87%) | 13 (81%) |
| Race, Caucasian (n, %) | 5 (83%) | 45 (75%) | 12 (75%) |
| SSc disease duration (months)* | 11 ± 3 | 38 ± 51 | |
| dcSSc (n, %) | 6 (100%) | 42 (70%) | |
| mRSS (median, IQR) | 15 (8) | 15 (8) | |
| Serum autoantibodies (n, %) | |||
| Anticentromere | 0 | 4 (7%) | |
| Anti-RNA polymerase III | 3 (50%) | 15 (25%) | |
| Anti-topoisomerase I (Scl-70) | 2 (33%) | 19 (31%) | |
*Months between date of onset of first non-Raynaud systemic sclerosis (SSc) symptom and date of skin biopsy. dcSSc Diffuse cutaneous SSc